Related Experiment Video
Updated: Jun 2, 2026
10:08
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
Published on: December 9, 2022
KCNQ2 Channel as a Druggable Epilepsy Target: Advances in Pharmacological Modifiers
Inn-Chi Lee1,2, Shi-Bing Yang3, Swee-Hee Wong1,4
1Division of Pediatric Neurology, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
CNS & Neurological Disorders Drug Targets
|June 1, 2026
Summary
Pathogenic variants in KCNQ2 cause severe neonatal epilepsies. New Kv7 activators show promise for targeting KCNQ2 channel dysfunction, offering potential mechanism-based therapies for Developmental and Epileptic Encephalopathy (DEE).
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- KCNQ2 gene variants are linked to neonatal epilepsies, including severe Developmental and Epileptic Encephalopathy (DEE).
- Current treatments for KCNQ2-related DEE are limited and do not specifically address the underlying Kv7.2 channel dysfunction.
- Existing Kv7 channel modulators like retigabine have safety concerns, necessitating the development of safer alternatives.
Purpose of the Study:
- To review the current understanding of KCNQ2 channelopathies and their impact on neuronal excitability.
- To explore the therapeutic potential of novel Kv7 channel activators for KCNQ2-related epilepsies.
- To discuss the challenges and future directions in developing mechanism-based therapies for DEE.
Main Methods:
- Literature review of KCNQ2 genetics, epilepsy phenotypes, and pharmacological interventions.
- Analysis of preclinical and clinical data on Kv7 channel modulators, including XEN1101.
- Examination of challenges in translating therapeutic efficacy to clinical outcomes in neonates.
Main Results:
- KCNQ2 variants cause a spectrum of neonatal epilepsies with significant neurodevelopmental impairment.
- Next-generation Kv7 activators demonstrate improved potency, selectivity, and tolerability compared to older agents.
- Limited evidence exists for the efficacy and safety of these new agents in pediatric populations, especially neonates.
Conclusions:
- KCNQ2 channels represent a druggable target for epilepsy, particularly for rare DEE subtypes.
- Developing targeted therapies that address Kv7.2 channel dysfunction is crucial for improving neurodevelopmental outcomes.
- Further research is needed to evaluate the safety, efficacy, and biomarkers of treatment response for novel Kv7 activators in children.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...